ImmunityBio
  • Our Science
    • Platforms
    • Pipeline
    • Expanded Access
  • Unique Approach
    • Patients
    • Trial Investigators
    • Researchers
  • Therapies
    • Pancreatic Cancer
    • Merkel Cell Carcinoma
    • Non-Small Cell Lung Cancer
    • Triple Negative Breast Cancer
    • Bladder Cancer
    • Glioblastoma
    • HIV
    • COVID-19
  • Our Company
    • About Us
    • Careers
    • Investor Relations
    • Contact
  • Research
  • News
  • Get Started
    • Join a Trial
    • Open a Trial
    • License Our Cells
Select Page

Combination therapy with the albumin-binding prodrug of doxorubicin (INNO-206) and doxorubicin achieves complete remissions and improves tolerability in an ovarian A2780 xenograft model.

by nantkweststg | Feb 12, 2021

Pharmacokinetic study of aldoxorubicin in patients with solid tumors.

by nantkweststg | Feb 12, 2021

Recent Posts

  • Jefferies Virtual Healthcare Conference
  • ImmunityBio Announces Single Prime hAd5 COVID-19 Vaccination Induces a 10-Fold Increase in T Cell Response Equivalent to T Cell Responses from Patients Previously Infected with SARS-CoV-2
  • ImmunityBio Appoints Dr. Linda Maxwell and CEO Richard Adcock to Board of Directors
  • ImmunityBio Announces 12-Month Overall Survival Probability of 83% in NCI-Led Phase 1 Study of Multi-Targeted hAd5 Immunotherapy Vaccine in Patients with Advanced Metastatic Prostate Cancer
  • ImmunityBio Announces NIH-Led Research Affirming that PD-L1 T-haNK Therapy Overcomes T-Cell Escape in Multiple Types of Resistant Tumors

Recent Comments

    Quicklinks

    • Pipeline
    • Careers
    • News and Events
    • Investor Relations
    • Contact

    Follow Us

    •  Facebook
    •  Twitter
    •  LinkedIn

    Legal

    • Privacy Policy
    • Legal Notice
    • Patent Notice

    © 2021 ImmunityBio, Inc. All Rights Reserved.

    A member of the NantWorks ecosystem of companies

    'Nantkwest’, ‘Conkwest’, ‘aNK’, ‘haNK’, ‘taNK’, ‘vaNK’, ’t-haNK’, ‘ceNK’, ‘M-ceNK’, ‘NK-92’, ‘Neukosome’, ‘Living Drugs in a Bag’, and ‘Nature’s First Responder’ are trademarks or registered trademarks of Nantkwest, Inc.

    Anktiva is a trademark of ImmunityBio, Inc.

    The Natural Killer Cell platform consists of investigational agents that are restricted by federal law to investigational use only.

    The Natural Killer Cell platform is being investigated in multiple clinical trials across tumor sites.

    The content of this website is protected by Title 17 of the U.S. Code and may not be reproduced in whole or in part by any means.